Cardiac Resynchronization Therapy Market Report 2025

This Cardiac Resynchronization Therapy market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The cardiac resynchronization therapy market size has grown strongly in recent years. It will grow from $6.29 billion in 2024 to $6.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to growth in the geriatric population, an increased incidence of heart failure, growth in investments in R&D for CRT device innovation, increased awareness about the therapy's benefits, physician training programs, and competitive landscape dynamics.

The cardiac resynchronization therapy market size is expected to see strong growth in the next few years. It will grow to $8.77 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to the increasing prevalence of heart failure and cardiac disorders, growth in the geriatric population, a higher incidence of cardiovascular diseases, the need for CRT therapy, improvements in pacemakers and defibrillator treatment, and increasing awareness about CRT therapy. Major trends in the forecast period include the adoption of CRT-D devices over traditional pacemakers, the integration of advanced technology, expansion of CRT therapy, the integration of artificial intelligence, and the adoption of machine learning.

The rising prevalence of cardiovascular diseases is expected to drive the growth of the cardiac resynchronization therapy (CRT) market. Cardiovascular diseases (CVD) encompass a range of conditions affecting the heart and blood vessels. The incidence of CVD is increasing due to factors such as aging populations, unhealthy lifestyles, high tobacco use, sedentary behavior, and poor dietary habits. Cardiac resynchronization therapy helps treat conditions like heart failure by improving the coordination of the heart's contractions through synchronized electrical impulses. For example, in September 2024, data from the Minnesota Department of Health, a US-based state health agency, revealed that approximately 30% of adults in Minnesota reported having high blood pressure in 2023, affecting nearly 1.4 million people. In 2022, hypertensive diseases were a contributing cause in 14,225 deaths in the state, accounting for almost 28% of all fatalities. As such, the growing prevalence of cardiovascular diseases is driving the demand for cardiac resynchronization therapy market.

The growing healthcare expenditure is expected to drive the expansion of the cardiac resynchronization therapy (CRT) market. Healthcare expenditure refers to the total spending on healthcare goods and services over a specific period, typically on a national or institutional level. Increased investment in healthcare can foster research and development in the field of cardiac resynchronization therapy, leading to advancements in technology, improved access to therapy, and a more comprehensive approach to healthcare systems. For example, in May 2023, the UK's Office for National Statistics reported a 9.4% nominal increase and a 9.7% practical increase in healthcare spending. In 2021, the UK's total healthcare spending was $367.25 billion (£280.7 billion), with pharmaceutical costs accounting for $51.84 billion (£39.6 billion). Spending on preventative care also surged in 2021, reaching $45.93 billion (£35.1 billion). Additionally, in September 2024, Cross River Therapy, a US-based provider of ABA therapy services, reported that the US pharmaceutical industry generated $550 billion in revenue, with Americans spending $576.9 billion on medicine in 2021. Projections suggest this spending will rise to $605-$635 billion by 2025. As a result, the increasing healthcare expenditure is driving the growth of the cardiac resynchronization therapy market.

Leading companies in the cardiac resynchronization therapy market are concentrating on the development of implantable devices to enhance treatment outcomes for heart failure patients. Implantable devices in CRT synchronize the contractions of the heart's ventricles, improving pumping efficiency and managing heart failure symptoms. For instance, MicroPort Scientific Corporation launched the GALI SonR cardiac resynchronization therapy and defibrillation device (CRT-D) and the Navigo 4LV left ventricular pacing leads in Japan in February 2024. This innovative CRT-D device incorporates the first and only CRT hemodynamic sensor, designed to automatically optimize patients on a weekly basis, even during physical activity, thus ensuring real-life optimization. The clinically proven SonR algorithm has demonstrated a 35% reduction in the risk of heart failure hospitalization, contributing to the well-being and safety of CRT-D patients.

Major companies operating in the cardiac resynchronization therapy market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, Biotronik SE & Co. KG, Lepu Medical Technology (Beijing) Co. Ltd., Integer Holdings Corporation, Merit Medical Systems Inc., LivaNova PLC, MicroPort Scientific Corporation, Sorin Group, Berlin Heart GmbH, EBR Systems Inc., Corvia Medical Inc., Recor Medical, Jarvik Heart Inc., Cardiac Dimensions Inc., Farapulse Inc., Osypka Medical GmbH, Japan Medical Device Corporation, Imricor Medical Systems Inc., Vascular Dynamics Inc., Svelte Medical Systems, Aleva Neurotherapeutics, BioSig Technologies Inc.

North America was the largest region in the cardiac resynchronization therapy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac resynchronization therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac resynchronization therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cardiac resynchronization therapy (CRT) is a treatment for heart failure aimed at synchronizing the contractions of the heart's ventricles. This therapy utilizes a biventricular pacemaker to administer electrical impulses to the heart muscle, thereby promoting a more coordinated rhythm of ventricular contractions. It has the potential to alleviate symptoms of heart failure, such as shortness of breath and fatigue, while also enhancing overall cardiac function.

The primary types of cardiac resynchronization therapy include cardiac resynchronization therapy (CRT)-defibrillator and cardiac resynchronization therapy (CRT)-pacemaker. A cardiac resynchronization therapy (CRT) defibrillator is a medical device designed to regulate heartbeats and deliver electrical shocks when irregular heart rhythms occur. These devices are utilized across various age groups, including patients below 44 years, 45-64 years, 65-84 years, and those aged above 85 years, by hospitals, cardiac care centers, and ambulatory surgical centers.

The cardiac resynchronization therapy market research report is one of a series of new reports that provides cardiac resynchronization therapy market statistics, including cardiac resynchronization therapy industry global market size, regional shares, competitors with a cardiac resynchronization therapy market share, detailed cardiac resynchronization therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac resynchronization therapy industry. This cardiac resynchronization therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiac resynchronization therapy market consists of revenues earned by entities by providing services such as patient evaluation and diagnosis, device implantation procedures, device programming, follow-up care, management of complications, patient education, and collaborative care involving a multidisciplinary team. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac resynchronization therapy market also includes sales of pacemakers or defibrillators, leads, programmers, accessories, diagnostic tools, patient monitoring devices, and educational materials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.